{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:15:09Z","timestamp":1780337709529,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-024-03361-7","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T07:04:07Z","timestamp":1730099047000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Usefulness of monitoring mycophenolic acid exposure in systemic sclerosis-related interstitial lung disease: a retrospective cohort study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6230-1570","authenticated-orcid":false,"given":"Jules","family":"Milesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Sampol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Benyamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shani","family":"Diai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Coiffard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Nieves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Granel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Reynaud-Gaubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Bermudez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"issue":"3","key":"3361_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1568-9972(03)00004-1","volume":"2","author":"MC Tamby","year":"2003","unstructured":"Tamby MC, Chanseaud Y, Guillevin L, Mouthon L. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev. 2003;2(3):152\u20137.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"3361_CR2","doi-asserted-by":"publisher","first-page":"A311","DOI":"10.1016\/j.autrev.2009.11.003","volume":"9","author":"B Ranque","year":"2010","unstructured":"Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev. 2010;9(5):A311\u2013318.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"3361_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/0002-9343(69)90044-8","volume":"46","author":"WA D\u2019Angelo","year":"1969","unstructured":"D\u2019Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46(3):428\u201340.","journal-title":"Am J Med"},{"issue":"127","key":"3361_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1183\/09059180.00005512","volume":"22","author":"JJ Solomon","year":"2013","unstructured":"Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respir Rev. 2013;22(127):6\u201319.","journal-title":"Eur Respir Rev"},{"issue":"9","key":"3361_CR5","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/art.1780370903","volume":"37","author":"VD Steen","year":"1994","unstructured":"Steen VD, Conte C, Owens GR, Medsger TA. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37(9):1283\u20139.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"3361_CR6","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","volume":"76","author":"M Elhai","year":"2017","unstructured":"Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76(11):1897\u2013905.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3361_CR7","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327\u201339.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"3361_CR8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s13023-021-01844-y","volume":"16","author":"E Hachulla","year":"2021","unstructured":"Hachulla E, Agard C, Allanore Y, Avouac J, Bader-Meunier B, Belot A, et al. French recommendations for the management of systemic sclerosis. Orphanet J Rare Dis. 2021;16(Suppl 2):322.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"3361_CR9","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708\u201319.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"3361_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2133\/dmpk.DMPK-13-RV-112","volume":"29","author":"M Dong","year":"2014","unstructured":"Dong M, Fukuda T, Vinks AA. Optimization of mycophenolic acid therapy using clinical pharmacometrics. Drug Metab Pharmacokinet. 2014;29(1):4\u201311.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"3361_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/jcph.1565","volume":"60","author":"J Benjanuwattra","year":"2020","unstructured":"Benjanuwattra J, Pruksakorn D, Koonrungsesomboon N. Mycophenolic Acid and Its Pharmacokinetic Drug-Drug Interactions in Humans: review of the evidence and clinical implications. J Clin Pharmacol. 2020;60(3):295\u2013311.","journal-title":"J Clin Pharmacol"},{"issue":"21","key":"3361_CR12","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219\u201328.","journal-title":"N Engl J Med."},{"issue":"3","key":"3361_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.autrev.2006.11.001","volume":"6","author":"L Iaccarino","year":"2007","unstructured":"Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttinic P, Doria A. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev. 2007;6(3):190\u20135.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"3361_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.det.2011.06.012","volume":"29","author":"M Eskin-Schwartz","year":"2011","unstructured":"Eskin-Schwartz M, David M, Mimouni D. Mycophenolate mofetil for the management of autoimmune bullous diseases. Dermatol Clin. 2011;29(4):555\u20139.","journal-title":"Dermatol Clin"},{"issue":"2","key":"3361_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/cei.12246","volume":"176","author":"B Chaigne","year":"2014","unstructured":"Chaigne B, Gatault P, Darrouzain F, Barbet C, Degenne D, Fran\u00e7ois M, et al. Mycophenolate mofetil in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a prospective pharmacokinetics and clinical study. Clin Exp Immunol. 2014;176(2):172\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"3361_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/01.ftd.0000199358.80013.bd","volume":"28","author":"T van Gelder","year":"2006","unstructured":"van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28(2):145\u201354.","journal-title":"Ther Drug Monit"},{"issue":"7","key":"3361_CR17","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1002\/art.27495","volume":"62","author":"N Zahr","year":"2010","unstructured":"Zahr N, Arnaud L, Marquet P, Haroche J, Costedoat-Chalumeau N, Hulot JS, et al. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum. 2010;62(7):2047\u201354.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"3361_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12185-011-0888-6","volume":"94","author":"K Wakahashi","year":"2011","unstructured":"Wakahashi K, Yamamori M, Minagawa K, Ishii S, Nishikawa S, Shimoyama M, et al. Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation. Int J Hematol. 2011;94(2):193\u2013202.","journal-title":"Int J Hematol"},{"issue":"11","key":"3361_CR19","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A Fern\u00e1ndez-Codina","year":"2018","unstructured":"Fern\u00e1ndez-Codina A, Walker KM, Pope JE, Scleroderma Algorithm Group. Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheumatol. 2018;70(11):1820\u20138.","journal-title":"Arthritis Rheumatol"},{"key":"3361_CR20","doi-asserted-by":"publisher","first-page":"152270","DOI":"10.1016\/j.semarthrit.2023.152270","volume":"63","author":"G Alex","year":"2023","unstructured":"Alex G, Shanoj KC, Varghese DR, SageerBabu AS, Reji R, Shenoy PD. Co prescription of anti-acid therapy reduces the bioavailability of mycophenolate mofetil in systemic sclerosis patients: a crossover trial. Semin Arthritis Rheum. 2023;63:152270.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"3361_CR21","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13075-020-02323-8","volume":"22","author":"K Andr\u00e9asson","year":"2020","unstructured":"Andr\u00e9asson K, Neringer K, Wuttge DM, Henrohn D, Marsal J, Hesselstrand R. Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation-a prospective, observational study. Arthritis Res Ther. 2020;22(1):230.","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"3361_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/2397198320944342","volume":"6","author":"P Legendre","year":"2021","unstructured":"Legendre P, Blanchet B, Porcher R, B\u00e9rezn\u00e9 A, Allard M, London J, et al. Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and\/or pulmonary involvement: a monocentric and retrospective French study. J Scleroderma Relat Disord. 2021;6(1):87\u201395.","journal-title":"J Scleroderma Relat Disord"},{"issue":"11","key":"3361_CR23","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","volume":"7","author":"Y Le Meur","year":"2007","unstructured":"Le Meur Y, B\u00fcchler M, Thierry A, Caillard S, Villemain F, Lavaud S, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007;7(11):2496\u2013503.","journal-title":"Am J Transplant"},{"issue":"2","key":"3361_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","volume":"43","author":"S Bergan","year":"2021","unstructured":"Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, et al. Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2021;43(2):150\u2013200.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"3361_CR25","doi-asserted-by":"publisher","first-page":"e001093","DOI":"10.1136\/lupus-2023-001093","volume":"11","author":"T Wuttiputhanun","year":"2024","unstructured":"Wuttiputhanun T, Naiyarakseree N, Udomkarnjananun S, Kittanamongkolchai W, Asada L, Chariyavilaskul P, et al. Therapeutic drug monitoring of mycophenolic acid and clinical outcomes of lupus nephritis: a systematic review and meta-analysis. Lupus Sci Med. 2024;11(1):e001093.","journal-title":"Lupus Sci Med"},{"issue":"11","key":"3361_CR26","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747\u201355.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3361_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1055\/s-0034-1371541","volume":"35","author":"AU Wells","year":"2014","unstructured":"Wells AU, Margaritopoulos GA, Antoniou KM, Denton C. Interstitial lung disease in systemic sclerosis. Semin Respir Crit Care Med. 2014;35(2):213\u201321.","journal-title":"Semin Respir Crit Care Med"},{"issue":"9","key":"3361_CR28","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3361_CR29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1373\/clinchem.2003.024323","volume":"50","author":"F Streit","year":"2004","unstructured":"Streit F, Shipkova M, Armstrong VW, Oellerich M. Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total mycophenolic acid. Clin Chem. 2004;50(1):152\u20139.","journal-title":"Clin Chem"},{"issue":"8","key":"3361_CR30","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/rheumatology\/kei211","volume":"45","author":"SNC Liossis","year":"2006","unstructured":"Liossis SNC, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford). 2006;45(8):1005\u20138.","journal-title":"Rheumatology (Oxford)."},{"issue":"2","key":"3361_CR31","first-page":"287","volume":"25","author":"M Vanthuyne","year":"2007","unstructured":"Vanthuyne M, Blockmans D, Westhovens R, Roufosse F, Cogan E, Coche E, et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol. 2007;25(2):287\u201392.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"3361_CR32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1513\/AnnalsATS.202301-054OC","volume":"21","author":"D Herman","year":"2024","unstructured":"Herman D, Ghazipura M, Barnes H, Macrea M, Knight SL, Silver RM, et al. Mycophenolate in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis. Ann Am Thorac Soc. 2024;21(1):136\u201350.","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"3361_CR33","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3899\/jrheum.111229","volume":"39","author":"FA Mendoza","year":"2012","unstructured":"Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol. 2012;39(6):1241\u20137.","journal-title":"J Rheumatol"},{"issue":"6","key":"3361_CR34","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1136\/ard.2010.142000","volume":"70","author":"EN Le","year":"2011","unstructured":"Le EN, Wigley FM, Shah AA, Boin F, Hummers LK. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2011;70(6):1104\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3361_CR35","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/rheumatology\/kep295","volume":"48","author":"CT Derk","year":"2009","unstructured":"Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford). 2009;48(12):1595\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3361_CR36","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/bcp.12462","volume":"78","author":"C Streicher","year":"2014","unstructured":"Streicher C, Djabarouti S, Xuereb F, Lazaro E, Legeron R, Bouchet S, et al. Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases. Br J Clin Pharmacol. 2014;78(6):1419\u201325.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"3361_CR37","doi-asserted-by":"publisher","first-page":"i138","DOI":"10.1093\/ndt\/gfv065","volume":"30","author":"M Schaier","year":"2015","unstructured":"Schaier M, Scholl C, Scharpf D, Schmitt WH, Schwenger V, Zeier M, et al. High interpatient variability in response to mycophenolic acid maintenance therapy in patients with ANCA-associated vasculitis. Nephrol Dial Transplant. 2015;30(Suppl 1):i138\u2013145.","journal-title":"Nephrol Dial Transplant"},{"issue":"18","key":"3361_CR38","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03361-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03361-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03361-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T23:02:51Z","timestamp":1730156571000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03361-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3361"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03361-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4919161\/v1","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board of the French learned society for respiratory medicine -Soci\u00e9t\u00e9 de Pneumologie de Langue Fran\u00e7aise- approved the protocol (CEPRO 2023\u2013014), and a written information and non-objection notice was given to all participants according to French law.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A written information and non-objection notice was given to all participants according to French law.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"537"}}